Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing
5 min read
--Advancing 11 clinical-stage assets across psychiatric conditions with Phase 2 data readouts in MDD and PTSD for each of its three lead candidates...
expected by mid-2023--

--Over $40 million in capital raised, including a $32 million Series A investment led by Apeiron Investment Group with participation from leading investors--

--Platform based on seminal work at Stanford University by founder Amit Etkin, M.D., Ph.D.--

LOS ALTOS, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Alto Neuroscience today announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. By leveraging its proprietary artificial intelligence (AI)-based brain biomarker platform, the company is advancing 11 clinical-stage assets, with three currently in Phase 2a studies for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The company anticipates Phase 2 data readouts in these indications for each drug candidate by mid-2023.

Alto's platform evolved out of more than a decade of clinical neuroscience research from the distinguished Etkin Lab at Stanford University and has since been validated by numerous publications in high-impact, peer-reviewed academic journals. This work was also recognized by the National Institutes of Health through the prestigious Director's Pioneer Award received by Dr. Etkin, the first to be awarded in clinical psychiatry. Recognizing the therapeutic potential of these findings, Dr. Etkin is departing a tenured professorship at Stanford to continue leading Alto with the goal of revolutionizing the diagnosis and treatment of mental health conditions.

"For years, I personally witnessed the limitations of existing mental health treatments and lack of innovation in the space when caring for my own patients," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. "Our precision psychiatry platform enables us, for the first time, to take differences in an individual's biology into consideration to identify the right treatment from those we are developing. We believe this paradigm shift will…
Alto Neuroscience
Read full article